Corvus Pharmaceuticals, Inc. (CRVS): 1 insider purchase in the last two years.
| Filed | Insider | Shares | Price | Value | Type |
|---|---|---|---|---|---|
| Jun 15, 2026 | Moore David Scott Director | 21,700 | $11.53 | $250.2K | no history |
Open-market purchases from SEC Form 4. "Opportunistic" = this insider trades every year but not on a fixed schedule (Cohen, Malloy & Pomorski); "routine" buys carry little information.
Free account. Know when insiders, famous funds or Congress trade it.